HIGH RISK HLA-A2+ MELANOMA

Clinical trials for HIGH RISK HLA-A2+ MELANOMA explained in plain language.

Never miss a new study

Get alerted when new HIGH RISK HLA-A2+ MELANOMA trials appear

Sign up with your email to follow new studies for HIGH RISK HLA-A2+ MELANOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Experimental vaccine aims to train immune system to fight returning melanoma

Disease control Terminated

This study tested a modified tumor cell vaccine designed to boost the body's immune system to attack melanoma cells. It was intended for patients with high-risk melanoma or those with a small amount of disease remaining after initial treatment. The goal was to see if the vaccine …

Matched conditions: HIGH RISK HLA-A2+ MELANOMA

Phase: PHASE2, PHASE3 • Sponsor: Hadassah Medical Organization • Aim: Disease control

Last updated Apr 01, 2026 14:42 UTC

HIGH RISK HLA-A2+ MELANOMA

Get alerted when new HIGH RISK HLA-A2+ MELANOMA trials appear

Experimental vaccine aims to train immune system to fight returning melanoma